Sorin Crm Sas

Institut National De La Sante Et De La Recherche Medicale

Université Joseph Fourier

Université De Rennes 1

Université Grenoble Alpes

Inserm (institut National De La Sante Et De La Recherche Medicale)

Delphine Feuerstein

Rafael Cordero Alvarez

Thierry Legay

Alfredo Hernandez

Amel Amblard

Paola Milpied

Marie-Anne Euzen

Laurence Graindorge

Jean-Louis Pépin

A subcutaneous implantable active medical device, in particular a subcutaneous cardiac defibrillator, comprising a housing and a subcutaneous implantable lead connected to the housing. The subcutaneous implantable lead comprises a plurality of sensing electrodes forming at least two dipoles from which at least two electrical signals are collected concurrently. The first dipole having a first length less than a second length of the second dipole. The subcutaneous implantable active medical device further comprises a controller configured to determine whether or not tachyarrhythmia is present by determining a criterion of similarity based on the electrical signals collected concurrently via the first dipole and via the second dipole during a defined series of cardiac cycles that is such that detection of a depolarization peak, corresponding to detection of an R wave, is performed via the first dipole.

Subcutaneous implantable medical device and a method of processing signals of a subcutaneous implantable medical device

A cardiac defibrillation system. The system comprising a housing and an implantable lead. The implantable lead comprising two ends, including a first end connected to the housing and a second end being a free end. The implantable lead also comprising a defibrillation electrode and at least three detection electrodes including a first detection electrode, a second detection electrode, and a third detection electrode. The first detection electrode and the second detection electrode forming a first dipole. The third detection electrode and the first detection electrode, or, the third detection electrode and the second detection electrode, or, the housing and one of said detection electrodes, forming a second dipole, where a length of the first dipole is between 5 and 50 millimeters and a length of the second dipole is between 50 and 400 millimeters.

Subcutaneous implantable cardiac defibrillation system

Disclosed are systems, devices and methods that produce at least two distinct temporal components from two distinct endocardial electrogram (EGM) signals collected concurrently, determines a non-temporal 2D characteristic representative of the cardiac cycle to be analyzed, from the variations of one of the temporal components as a function of another of the temporal components and comparing the characteristic of the current cycle to two reference characteristics previously obtained and stored, one in a situation of complete capture and the other in a situation of spontaneous rhythm. Respective values of similarity descriptors are derived of these two comparisons, which are used to calculate a metric quantifying a fusion rate.

Active implantable medical device for detecting and quantifying fusion

The present invention relates to a medical device, in particular to an implantable medical device, comprising at least one implantable or non-implantable hemodynamic sensor configured for detecting hemodynamic cardiac signals, a controller configured for processing and analyzing the detected cardiac hemodynamic signals or signals derived from the detected cardiac hemodynamic signals by applying to said signals a Teager Energy Operator (TEO). The controller further comprises at least one algorithm configured to determine the need for a defibrillation operation by taking into account the at least one output hemodynamic signal. The present invention also provides a method and software for detecting or treating a ventricular fibrillation episode by taking into account cardiac hemodynamic signals.

Device and method for detecting ventricular fibrillation

A subcutaneous cardiac defibrillation system implantable comprising a housing and a subcutaneous implantable lead comprising a proximal end connected to the housing and a distal free end. The subcutaneous implantable lead comprises at least one defibrillation electrode and at least three detection electrodes. The first detection electrode and the second detection electrode form a first dipole, and the third detection electrode and the first detection electrode, or the third detection electrode and the second detection electrode, or the housing and one of said detection electrodes, form a second dipole. The defibrillation electrode is positioned between the second detection electrode and the third detection electrode, the first dipole is positioned between the housing and the defibrillation electrode, the third electrode is positioned between the free distal end of the lead and the defibrillation electrode, and the length of the first dipole is shorter than the length of the second dipole.

This disclosure relates to an active implantable medical device of the cardiac resynchronizer type. The device includes a pulse generator to produce pacing pulses, at least one detection electrode for detecting atrial and ventricular events, at least one stimulation electrode, a memory storing executable instructions, and a processor configured to execute the instructions. The processor is configured to execute the instructions to apply an atrioventricular delay (AVD) between a sensed or stimulated atrial event and the delivery of a ventricular pacing pulse, quantify a degree of fusion between the delivery of a pacing pulse to a cavity and a spontaneous contraction of another cavity, calculate a fusion rate, and modify the value of the AVD applied to the delivery of said ventricular pacing pulse, as a function of a comparison.

Active implantable medical device such as a cardiac resynchroniser with dynamic adaptation of an atrioventricular delay depending on a detected and quantified degree of fusion

A system includes a processor configured to generate stimulation control signals in response to a detection of a respiratory disorder. The system further includes at least one kinesthetic effector with a vibrating electromechanical transducer applied to a site on a patient's skin for delivering a kinesthetic stimulation energy determined by the control signals. The processor is further configured to determine the effectiveness of a stimulation by detecting a cessation of the respiratory disorder. The processor is further configured to extend the stimulation control signals for a determined duration following the cessation of the respiratory disorder.

System for respiratory disorder therapy with stabilization control of stimulation

A device includes a processor configured to detect a respiratory disorder episode and generate kinesthetic stimulation control signals in response to the detection of a respiratory disorder episode. The device further includes at least one kinesthetic effector adapted to be applied to a patient's outer skin site and includes a vibrating electromechanical transducer capable of receiving stimulation control signals and outputting a kinesthetic stimulation energy determined by the stimulation control signals. The processor is further configured to determine the effectiveness of stimulation by detecting a cessation of the respiratory disorder episode. The processor is further configured to determine a stimulation energy by selecting an initial energy value and varying the energy value as a function of the effectiveness of previous stimulation.

Device for optimization of sleep apnea syndrome therapy by kinesthetic stimulation

A system includes a processor configured to generate stimulation control signals in response to a detection of a respiratory disorder. The system further includes at least one kinesthetic effector with a vibrating electromechanical transducer applied to a site on a patient's skin for delivering a kinesthetic stimulation energy determined by the control signals. The processor is further configured to determine the effectiveness of a stimulation by detecting a disappearance of the respiratory disorder. The processor is further configured to determine a therapy by selecting a stimulation strategy among several stimulation strategies according to a type of expected or detected disorder.

Growing community of inventors

Issy les Moulineaux, France

Delphine Feuerstein